Podcasts
Listen to the latest hemonc news from international experts
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
The Myeloma Sessions: smoldering myeloma, MRD evaluation, R/R disease & transplant-eligible patients
The multiple myeloma field is rapidly evolving, with exciting developments in strategies for the treatment of smoldering myeloma, relapsed/refractory (R/R) disease, and transplant-eligible patients. The impact of measurable residual disease (MRD) negativity in the clinical decision-making process for patients with multiple myeloma remains a hotly debated topic among the experts.
In this podcast, Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, chairs a discussion with Francesca Gay, MD, PhD, University of Turin, Turin, Italy, and Saad Usmani, MD, FACP, Levine Cancer Institute & Atrium Health, Charlotte, NC, on the most important updates and latest research evidence in multiple myeloma.
Date: 3rd July 2020
